UBS has raised its price target for Medtronic to $93, maintaining a Neutral rating, following the company"s second fiscal quarter performance that exceeded sales expectations. The firm highlights consistent mid-single-digit organic sales growth and positive momentum in the Diabetes segment, alongside the anticipated launch of new products like the Affera Mapping and Ablation System. Despite a slight deceleration in growth, Medtronic"s strong financials and dividend history position it favorably in the healthcare market.